Tianshui Zhongxing Bio-technology Co.,Ltd. (SHE:002772)
China · Delayed Price · Currency is CNY 15.72
-0.09 (-0.57%)
Mar 27, 2026, 3:04 PM CST
SHE:002772 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Operating Revenue | 2,098 | 1,933 | 1,931 | 1,970 | 1,556 |
Other Revenue | - | 2.7 | 0.15 | - | - |
| 2,098 | 1,935 | 1,931 | 1,970 | 1,556 | |
Revenue Growth (YoY) | 8.43% | 0.21% | -1.99% | 26.61% | 4.92% |
Cost of Revenue | 1,498 | 1,545 | 1,494 | 1,473 | 1,268 |
Gross Profit | 600.19 | 390.27 | 436.86 | 497.69 | 287.97 |
Selling, General & Admin | 249.44 | 242.97 | 241.43 | 242.26 | 208.75 |
Research & Development | 16.79 | 15.51 | 12.92 | 10.41 | 7.17 |
Other Operating Expenses | -17.75 | 2.54 | 1.03 | -0.12 | 0.39 |
Operating Expenses | 248.48 | 261.7 | 254.98 | 253.49 | 216.13 |
Operating Income | 351.72 | 128.57 | 181.88 | 244.21 | 71.85 |
Interest Expense | - | -76.85 | -83.61 | -90.49 | -80.87 |
Interest & Investment Income | 11.97 | 47.18 | 46.37 | 42.64 | 57.93 |
Currency Exchange Gain (Loss) | - | -4.15 | 4.77 | 2.11 | -7.69 |
Other Non Operating Income (Expenses) | -28.04 | -0.29 | -0.16 | -0.43 | -0.19 |
EBT Excluding Unusual Items | 335.65 | 94.46 | 149.26 | 198.04 | 41.04 |
Gain (Loss) on Sale of Investments | 12.93 | 15.22 | -10.56 | -53.62 | 13.43 |
Gain (Loss) on Sale of Assets | -6.54 | -2.49 | 0.01 | 0.18 | -0.03 |
Asset Writedown | -6.24 | -0.15 | -0.06 | -0.08 | -0 |
Other Unusual Items | - | 19.57 | 20.9 | 14.38 | -0.35 |
Pretax Income | 335.8 | 126.6 | 159.56 | 158.9 | 54.32 |
Income Tax Expense | 1.21 | - | - | 0 | - |
Earnings From Continuing Operations | 334.59 | 126.6 | 159.56 | 158.89 | 54.32 |
Minority Interest in Earnings | 0.37 | 1.43 | 0.03 | -0.54 | 0.65 |
Net Income | 334.96 | 128.03 | 159.58 | 158.35 | 54.97 |
Net Income to Common | 334.96 | 128.03 | 159.58 | 158.35 | 54.97 |
Net Income Growth | 161.63% | -19.77% | 0.78% | 188.08% | -70.91% |
Shares Outstanding (Basic) | 375 | 392 | 408 | 396 | 393 |
Shares Outstanding (Diluted) | 376 | 392 | 408 | 396 | 393 |
Shares Change (YoY) | -4.03% | -3.89% | 2.94% | 0.83% | 16.36% |
EPS (Basic) | 0.89 | 0.33 | 0.39 | 0.40 | 0.14 |
EPS (Diluted) | 0.89 | 0.33 | 0.39 | 0.40 | 0.14 |
EPS Growth | 172.62% | -16.52% | -2.10% | 185.71% | -75.00% |
Free Cash Flow | -55.55 | 249.36 | 395.48 | 247.84 | -700.15 |
Free Cash Flow Per Share | -0.15 | 0.64 | 0.97 | 0.63 | -1.78 |
Dividend Per Share | - | 0.300 | 0.300 | 0.300 | 0.100 |
Dividend Growth | - | - | - | 200.00% | - |
Gross Margin | 28.60% | 20.17% | 22.62% | 25.26% | 18.51% |
Operating Margin | 16.76% | 6.64% | 9.42% | 12.39% | 4.62% |
Profit Margin | 15.96% | 6.62% | 8.26% | 8.04% | 3.53% |
Free Cash Flow Margin | -2.65% | 12.89% | 20.48% | 12.58% | -44.99% |
EBITDA | 663.61 | 414.92 | 450.58 | 519.59 | 329.32 |
EBITDA Margin | 31.62% | 21.44% | 23.33% | 26.37% | 21.16% |
D&A For EBITDA | 311.89 | 286.35 | 268.7 | 275.39 | 257.48 |
EBIT | 351.72 | 128.57 | 181.88 | 244.21 | 71.85 |
EBIT Margin | 16.76% | 6.64% | 9.42% | 12.39% | 4.62% |
Effective Tax Rate | 0.36% | - | - | 0.00% | - |
Revenue as Reported | - | 1,935 | 1,931 | 1,970 | 1,556 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.